Abstract:Abstract Background Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are acid suppressant drugs indicated in highly prevalent conditions such as gastroesophageal reflux disease and peptic ulcer disease. A recent observational study reported an increased risk of inflammatory bowel disease (IBD) with the use of PPIs. However, this association may have been driven by certain methodological shortcomings, such as failure to properly account for protopathic bias, a conclusion-altering bias. Purpose To determine whether the use of PPIs compared with the use of H2RAs is associated with an increased risk of IBD. Method Using the longitudinal primary care records from the United Kingdom Clinical Practice Research Datalink database, we identified 1,498,416 initiators of PPIs and 322,474 initiators of H2RAs from January 1, 1990, through December 31, 2018, with follow-up until December 31, 2019. Standardized morbidity ratio weighted Cox proportional hazards models were used to estimate marginal hazard ratios (HRs) and 95% confidence intervals (CIs). Patients were analyzed according to the timing of the IBD events after treatment initiation (early versus late). In the early-event analysis, IBD events were assessed within the first two years of treatment initiation, an analysis subject to potential protopathic bias. In the late-event analysis, all exposures were lagged by two years to account for latency and minimize protopathic bias. Result(s) In the early-event analysis, the use of PPIs was associated with an increased risk of IBD within the first two years of treatment initiation, compared with H2RAs (HR: 1.39, 95% CI: 1.14-1.69). In contrast, the use of PPIs was not associated with an increased risk of IBD in the late-event analysis (HR: 1.05, 95% CI: 0.90 to 1.22). The results remained consistent in several sensitivity analyses. Image Conclusion(s) Compared with H2RAs, PPIs were not associated with an increased risk of IBD, after accounting for protopathic bias. Please acknowledge all funding agencies by checking the applicable boxes below CIHR Disclosure of Interest R. Yanofsky: None Declared, D. Abrahami Employee of: pfizer, R. Pradhan: None Declared, H. Yin: None Declared, E. McDonald: None Declared, A. Bitton Consultant of: Member of Advisory Boards for Abbie, Pfizer, Takeda, Jansen, and Merck, Speakers bureau of: Has received speaker fees for Abbie, Jansen, Takeda, and Pfizer, L. Azoulay Consultant of: Has received consults fees from Jansen, Pfizer, and Roche, Speakers bureau of: Has received speaker fees from Jansen, Pfizer, and Roche

Acid suppressants are associated with increased risk of intestinal infections, study finds

Do proton pump inhibitors increase the risk of serious infections?

Proton pump inhibitors alter the composition of the gut microbiota

Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study

Long-term Use of Proton Pump Inhibitors is Associated with an Increased Risk of Nonalcoholic Fatty Liver Disease

Proton-pump inhibitors increase infection risk by altering pH rather than by affecting the gut microbiome based on a bioreactor model

Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis

The Positive Association between Proton Pump Inhibitors and Clostridium Difficile Infection

Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota

The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H2 Receptor Antagonists with Clinical Complications in Patients with Severe Sepsis

Understanding the health risks and emerging concerns associated with the use of long-term proton pump inhibitors

Impact of short-term proton pump inhibitors vs. histamine-2 receptor antagonists on gut microbiota in patients with acute coronary syndrome: A multicenter randomized trial

Updated Meta-Analysis of Controlled Observational Studies: Proton-Pump Inhibitors and Risk of Clostridium Difficile Infection

Hospitalized Patients on Proton Pump Inhibitors for Stress Ulcer Prophylaxis Have a Higher Risk of Clostridioides difficile Infection Compared to Those on Histamine-2 Receptor Antagonists

Regular Use of Proton Pump Inhibitor and the Risk of Inflammatory Bowel Disease: Pooled Analysis of 3 Prospective Cohorts

A66 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY

S29 Proton Pump Inhibitor Use is Associated with Worse Clinical Outcomes in Patients with Inflammatory Bowel Disease

Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin

Use of proton pump inhibitor and risk of small intestinal bacterial overgrowth:a meta-analysis of observational studies

Acid suppressants use and risk of atherosclerotic cardiovascular disease in middle-aged and older adults

Vonoprazan-associated Clostridioides difficile infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System